Alternative splicing and breast cancer

RNA Biology

Volumn 7, Issue 4, 2010, Pages 403-411

  Dutertre, Martin ^a   Vagner, Stephan ^a   Auboeuf, Didier ^a  

^a INSERM   (France)

Author keywords

Breast; Cancer; Genetics; Metastasis; Splicing

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; MESSENGER RNA; RNA POLYMERASE II; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ALTERNATIVE RNA SPLICING; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CANCER GROWTH; CELL ADHESION; CELL MOTILITY; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; INTRON; PHENOTYPIC PLASTICITY; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN MODIFICATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA ANALYSIS; TUMOR SUPPRESSOR GENE;

EID: 77957307409     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.7.4.12152     Document Type: Review

References (132)

1. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458:1-7.
2. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Engl J Med 2002; 347:1593-603.
3. Bertucci F, Birnbaum D. Distant metastasis: not out of reach any more. J Biol 2009; 8:28.
4. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008; 14:818-29. (Pubitemid 351757205)
5. Weinberg RA. Mechanisms of malignant progression. Carcinogenesis 2008; 29:1092.
6. Weber GF. Molecular mechanisms of metastasis. Cancer Lett 2008; 270:181-90.
7. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006; 6:449-58.
8. Black DL. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 2003; 72:291-336. (Pubitemid 36930448)
9. Srebrow A, Kornblihtt AR. The connection between splicing and cancer. J Cell Sci 2006; 119:2635-41.
10. Caceres JF, Kornblihtt AR. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 2002; 18:186-93.
11. Smith CW, Valcarcel J. Alternative pre-mRNA splicing: the logic of combinatorial control. Trends Biochem Sci 2000; 25:381-8.
12. de la Grange P, Dutertre M, Correa M, Auboeuf D. A new advance in alternative splicing databases: from catalogue to detailed analysis of regulation of expression and function of human alternative splicing variants. BMC Bioinformatics 2007; 8:180. (Pubitemid 47018646)
13. de la Grange P, Dutertre M, Martin N, Auboeuf D. FAST DB: a website resource for the study of the expression regulation of human gene products. Nucleic Acids Res 2005; 33:4276-84. (Pubitemid 41487286)
14. Koscielny G, Le Texier V, Gopalakrishnan C, Kumanduri V, Riethoven JJ, Nardone F, et al. ASTD: The Alternative Splicing and Transcript Diversity database. Genomics 2009; 93:213-20.
15. Bhasi A, Philip P, Sreedharan VT, Senapathy P. AspAlt: A tool for inter-database, inter-genomic and user-specific comparative analysis of alternative transcription and alternative splicing in 46 eukaryotes. Genomics 2009.
16. Rajan P, Elliott DJ, Robson CN, Leung HY. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009; 6:454-60.
17. Pio R, Montuenga LM. Alternative splicing in lung cancer. J Thorac Oncol 2009; 4:674-8.
18. Grosso AR, Martins S, Carmo-Fonseca M. The emerging role of splicing factors in cancer. EMBO Rep 2008; 9:1087-93.
19. Kim E, Goren A, Ast G. Alternative splicing and disease. RNA Biol 2008; 5:17-9.
20. Pettigrew CA, Brown MA. Pre-mRNA splicing aberrations and cancer. Front Biosci 2008; 13:1090-105.
21. Fackenthal JD, Godley LA. Aberrant RNA splicing and its functional consequences in cancer cells. Dis Model Mech 2008; 1:37-42.
22. Pajares MJ, Ezponda T, Catena R, Calvo A, Pio R, Montuenga LM. Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol 2007; 8:349-57. (Pubitemid 46464532)
23. Skotheim RI, Nees M. Alternative splicing in cancer: noise, functional or systematic? Int J Biochem Cell Biol 2007; 39:1432-49.
24. Venables JP. Unbalanced alternative splicing and its significance in cancer. Bioessays 2006; 28:378-86.
25. Brinkman BM. Splice variants as cancer biomarkers. Clin Biochem 2004; 37:584-94.
26. Kalsotra A, Xiao X, Ward AJ, Castle JC, Johnson JM, Burge CB, Cooper TA. A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart. Proc Natl Acad Sci USA 2008; 105:20333-8.
27. Boutz PL, Chawla G, Stoilov P, Black DL. MicroRNAs regulate the expression of the alternative splicing factor nPTB during muscle development. Genes Dev 2007; 21:71-84. (Pubitemid 46089709)
28. de la Grange P, Gratadou L, Delord M, Dutertre M, Auboeuf D. Splicing factor and exon profiling across human tissues. Nucleic Acids Res.
29. Schwerk C, Schulze-Osthoff K. Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005; 19:1-13. (Pubitemid 40884653)
30. Jiang ZH, Wu JY. Alternative splicing and programmed cell death. Proc Soc Exp Biol Med 1999; 220:64-72. (Pubitemid 29048802)
31. Vegran F, Boidot R, Oudin C, Defrain C, Rebucci M, Lizard-Nacol S. Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer. Oncogene 2007; 26:290-7. (Pubitemid 46095740)
32. Boidot R, Vegran F, Lizard-Nacol S. Predictive value of survivin alternative transcript expression in locally advanced breast cancer patients treated with neoadjuvant chemotherapy. Int J Mol Med 2009; 23:285-91.
33. Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452:230-3. (Pubitemid 351380249)
34. David CJ, Chen M, Assanah M, Canoll P, Manley JL. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature; 463:364-8.
35. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, Turley H, et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000; 83:63-8.
36. Harper SJ, Bates DO. VEGF-A splicing: the key to anti-angiogenic therapeutics? Nat Rev Cancer 2008; 8:880-7.
37. Elkin M, Orgel A, Kleinman HK. An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. J Natl Cancer Inst 2004; 96:875-8.
38. Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, et al. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell 2005; 20:881-90.
39. Wang MH, Yao HP, Zhou YQ. Oncogenesis of RON receptor tyrosine kinase: a molecular target for malignant epithelial cancers. Acta Pharmacol Sin 2006; 27:641-50.
40. Mirza M, Shaughnessy E, Hurley JK, Vanpatten KA, Pestano GA, He B, et al. Osteopontin-c is a selective marker of breast cancer. Int J Cancer 2008; 122:889-97.
41. He B, Mirza M, Weber GF. An osteopontin splice variant induces anchorage independence in human breast cancer cells. Oncogene 2006; 25:2192-202.
42. Goncalves V, Matos P, Jordan P. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum Mol Genet 2009; 18:3696-707.
43. Radisky DC, Levy DD, Littlepage LE, Liu H, Nelson CM, Fata JE, et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436:123-7. (Pubitemid 40966197)
44. Cha JY, Lambert QT, Reuther GW, Der CJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res 2008; 6:435-45.
45. Chaffer CL, Dopheide B, Savagner P, Thompson EW, Williams ED. Aberrant fibroblast growth factor receptor signaling in bladder and other cancers. Differentiation 2007; 75:831-42.
46. Moffa AB, Tannheimer SL, Ethier SP. Transforming potential of alternatively spliced variants of fibroblast growth factor receptor 2 in human mammary epithelial cells. Mol Cancer Res 2004; 2:643-52.
47. Oltean S, Sorg BS, Albrecht T, Bonano VI, Brazas RM, Dewhirst MW, et al. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci USA 2006; 103:14116-21. (Pubitemid 44452989)
48. Warzecha CC, Sato TK, Nabet B, Hogenesch JB, Carstens RP. ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell 2009; 33:591-601.
49. Warzecha CC, Shen S, Xing Y, Carstens RP. The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biol 2009; 6:546-62.
50. He C, Zhou F, Zuo Z, Cheng H, Zhou R. A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis. PLoS One 2009; 4:4732.
51. Kim E, Goren A, Ast G. Insights into the connection between cancer and alternative splicing. Trends Genet 2008; 24:7-10. (Pubitemid 350298628)
52. Ritchie W, Granjeaud S, Puthier D, Gautheret D. Entropy measures quantify global splicing disorders in cancer. PLoS Comput Biol 2008; 4:1000011. (Pubitemid 351497526)
53. He C, Zuo Z, Chen H, Zhang L, Zhou F, Cheng H, et al. Genome-wide detection of testis- and testicular cancer-specific alternative splicing. Carcinogenesis 2007; 28:2484-90. (Pubitemid 350238950)
54. Venables JP, Klinck R, Bramard A, Inkel L, Dufresne-Martin G, Koh C, et al. Identification of alternative splicing markers for breast cancer. Cancer Res 2008; 68:9525-31.
55. Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L, et al. Cancer-associated regulation of alternative splicing. Nat Struct Mol Biol 2009; 16:670-6.
56. Clark TA, Schweitzer AC, Chen TX, Staples MK, Lu G, Wang H, et al. Discovery of tissue-specific exons using comprehensive human exon microarrays. Genome Biol 2007; 8:64.
57. Hallegger M, Llorian M, Smith CW. Alternative splicing: global insights. FEBS J.
58. Relogio A, Ben-Dov C, Baum M, Ruggiu M, Gemund C, Benes V, et al. Alternative splicing microarrays reveal functional expression of neuron-specific regulators in Hodgkin lymphoma cells. J Biol Chem 2005; 280:4779-84. (Pubitemid 40288649)
59. French PJ, Peeters J, Horsman S, Duijm E, Siccama I, van den Bent MJ, et al. Identification of differentially regulated splice variants and novel exons in glial brain tumors using exon expression arrays. Cancer Res 2007; 67:5635-42. (Pubitemid 46984994)
60. Gardina PJ, Clark TA, Shimada B, Staples MK, Yang Q, Veitch J, et al. Alternative splicing and differential gene expression in colon cancer detected by a whole genome exon array. BMC Genomics 2006; 7:325.
61. Thorsen K, Sorensen KD, Brems-Eskildsen AS, Modin C, Gaustadnes M, Hein AM, et al. Alternative splicing in colon, bladder and prostate cancer identified by exon array analysis. Mol Cell Proteomics 2008; 7:1214-24.
62. Xi L, Feber A, Gupta V, Wu M, Bergemann AD, Landreneau RJ, et al. Whole genome exon arrays identify differential expression of alternatively spliced, cancer-related genes in lung cancer. Nucleic Acids Res 2008; 36:6535-47.
63. André F, Michiels S, Dessen P, Scott V, Suciu V, Uzan C, et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 2009; Early Online Publication 2009.
64. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52:1399-405.
65. Dutertre M, Lacroix-Triki M, Driouch K, de la Grange P, Gratadou L, Beck S, et al. Exon-Based Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose Expression Is Associated with Metastasis. Cancer Res.
66. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res 2005; 3:1-13.
67. Thill G, Castelli V, Pallud S, Salanoubat M, Wincker P, de la Grange P, et al. ASEtrap: a biological method for speeding up the exploration of spliceomes. Genome Res 2006; 16:776-86.
68. Venables JP, Burn J. EASI - enrichment of alternatively spliced isoforms. Nucleic Acids Res 2006; 34:103.
69. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet 2008; 40:1413-5.
70. Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, et al. Alternative isoform regulation in human tissue transcriptomes. Nature 2008; 456:470-6. (Pubitemid 352759009)
71. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
72. Raponi M, Baralle D. Alternative splicing: good and bad effects of translationally silent substitutions. FEBS J.
73. Lopez-Bigas N, Audit B, Ouzounis C, Parra G, Guigo R. Are splicing mutations the most frequent cause of hereditary disease? FEBS Lett 2005; 579:1900-3.
74. Xing Y, Lee C. Alternative splicing and RNA selection pressure - evolutionary consequences for eukaryotic genomes. Nat Rev Genet 2006; 7:499-509. (Pubitemid 43943568)
75. Venkitaraman AR. Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 2009; 4:461-87.
76. Bonnet C, Krieger S, Vezain M, Rousselin A, Tournier I, Martins A, et al. Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 2008; 45:438-46. (Pubitemid 351977134)
77. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007; 81:873-83. (Pubitemid 47580242)
78. Lovelock PK, Healey S, Au W, Sum EY, Tesoriero A, Wong EM, et al. Genetic, functional and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 2006; 43:74-83. (Pubitemid 43102586)
79. Tommasi S, Pilato B, Pinto R, Monaco A, Bruno M, Campana M, et al. Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 2008; 644:64-70.
80. Farrugia DJ, Agarwal MK, Pankratz VS, Deffenbaugh AM, Pruss D, Frye C, et al. Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Res 2008; 68:3523-31.
81. Caux-Moncoutier V, Pages-Berhouet S, Michaux D, Asselain B, Castera L, De Pauw A, et al. Impact of BRCA1 and BRCA2 variants on splicing: clues from an allelic imbalance study. Eur J Hum Genet 2009; 17:1471-80.
82. Anczukow O, Buisson M, Salles MJ, Triboulet S, Longy M, Lidereau R, et al. Unclassified variants identified in BRCA1 exon 11: Consequences on splicing. Genes Chromosomes Cancer 2008; 47:418-26. (Pubitemid 351451796)
83. Millevoi S, Bernat S, Telly D, Fouque F, Gladieff L, Favre G, et al. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. Breast Cancer Res Treat 2009.
84. Liu HX, Cartegni L, Zhang MQ, Krainer AR. A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 2001; 27:55-8.
85. Kim MY, Hur J, Jeong S. Emerging roles of RNA and RNA-binding protein network in cancer cells. BMB Rep 2009; 42:125-30.
86. Reyal F, van Vliet MH, Armstrong NJ, Horlings HM, de Visser KE, Kok M, et al. A comprehensive analysis of prognostic signatures reveals the high predictive capacity of the proliferation, immune response and RNA splicing modules in breast cancer. Breast Cancer Res 2008; 10:93.
87. Galante PA, Sandhu D, de Sousa Abreu R, Gradassi M, Slager N, et al. A comprehensive in silico expression analysis of RNA binding proteins in normal and tumor tissue: Identification of potential players in tumor formation. RNA Biol 2009; 6:426-33.
88. Kirschbaum-Slager N, Lopes GM, Galante PA, Riggins GJ, de Souza SJ. Splicing factors are differentially expressed in tumors. Genet Mol Res 2004; 3:512-20.
89. Watermann DO, Tang Y, Zur Hausen A, Jager M, Stamm S, Stickeler E. Splicing factor Tra2-beta1 is specifically induced in breast cancer and regulates alternative splicing of the CD44 gene. Cancer Res 2006; 66:4774-80.
90. Zhou J, Allred DC, Avis I, Martinez A, Vos MD, Smith L, et al. Differential expression of the early lung cancer detection marker, heterogeneous nuclear ribonucleoprotein-A2/B1 (hnRNP-A2/B1) in normal breast and neoplastic breast cancer. Breast Cancer Res Treat 2001; 66:217-24.
91. Karni R, Hippo Y, Lowe SW, Krainer AR. The splicing-factor oncoprotein SF2/ASF activates mTORC1. Proc Natl Acad Sci USA 2008; 105:15323-7.
92. Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR. The gene encoding the splicing factor SF2/ ASF is a proto-oncogene. Nat Struct Mol Biol 2007; 14:185-93. (Pubitemid 46355578)
93. Huang CS, Shen CY, Wang HW, Wu PE, Cheng CW. Increased expression of SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node metastasis in human breast cancer. Clin Chim Acta 2007; 384:69-74.
94. Blaustein M, Pelisch F, Srebrow A. Signals, pathways and splicing regulation. Int J Biochem Cell Biol 2007; 39:2031-48.
95. Tarn WY. Cellular signals modulate alternative splicing. J Biomed Sci 2007; 14:517-22.
96. Stamm S. Regulation of alternative splicing by reversible protein phosphorylation. J Biol Chem 2008; 283:1223-7.
97. Stamm S. Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet 2002; 11:2409-16. (Pubitemid 35174704)
98. Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic and pancreatic carcinomas. Cancer Res 2007; 67:2072-80.
99. Zorio DA, Bentley DL. The link between mRNA processing and transcription: communication works both ways. Exp Cell Res 2004; 296:91-7.
100. Chen M, Manley JL. Mechanisms of alternative splicing regulation: insights from molecular and genomics approaches. Nat Rev Mol Cell Biol 2009; 10:741-54.
101. Listerman I, Sapra AK, Neugebauer KM. Cotranscriptional coupling of splicing factor recruitment and precursor messenger RNA splicing in mammalian cells. Nat Struct Mol Biol 2006; 13:815-22. (Pubitemid 44338776)
102. Wetterberg I, Bauren G, Wieslander L. The intranuclear site of excision of each intron in Balbiani ring 3 pre-mRNA is influenced by the time remaining to transcription termination and different excision efficiencies for the various introns. RNA 1996; 2:641-51. (Pubitemid 26374216)
103. Bittencourt D, Dutertre M, Sanchez G, Barbier J, Gratadou L, Auboeuf D. Cotranscriptional splicing potentiates the mRNA production from a subset of estradiol-stimulated genes. Mol Cell Biol 2008; 28:5811-24.
104. Ghosh S, Garcia-Blanco MA. Coupled in vitro synthesis and splicing of RNA polymerase II transcripts. RNA 2000; 6:1325-34.
105. Das R, Dufu K, Romney B, Feldt M, Elenko M, Reed R. Functional coupling of RNAP II transcription to spliceosome assembly. Genes Dev 2006; 20:1100-9.
106. Nogues G, Kadener S, Cramer P, de la Mata M, Fededa JP, Blaustein M, et al. Control of alternative pre-mRNA splicing by RNA Pol II elongation: faster is not always better. IUBMB Life 2003; 55:235-41. (Pubitemid 36842254)
107. de la Mata M, Alonso CR, Kadener S, Fededa JP, Blaustein M, Pelisch F, et al. A slow RNA polymerase II affects alternative splicing in vivo. Mol Cell 2003; 12:525-32. (Pubitemid 37238937)
108. Munoz MJ, Perez Santangelo MS, Paronetto MP, de la Mata M, Pelisch F, Boireau S, et al. DNA damage regulates alternative splicing through inhibition of RNA polymerase II elongation. Cell 2009; 137:708-20.
109. Auboeuf D, Dowhan DH, Kang YK, Larkin K, Lee JW, Berget SM, et al. Differential recruitment of nuclear receptor coactivators may determine alternative RNA splice site choice in target genes. Proc Natl Acad Sci USA 2004; 101:2270-4. (Pubitemid 38269301)
110. Auboeuf D, Honig A, Berget SM, O'Malley BW. Coordinate regulation of transcription and splicing by steroid receptor coregulators. Science 2002; 298:416-9. (Pubitemid 35176350)
111. Sanchez G, Bittencourt D, Laud K, Barbier J, Delattre O, Auboeuf D, et al. Alteration of cyclin D1 transcript elongation by a mutated transcription factor upregulates the oncogenic D1b splice isoform in cancer. Proc Natl Acad Sci USA 2008; 105:6004-9.
112. Sanchez G, Delattre O, Auboeuf D, Dutertre M. Coupled alteration of transcription and splicing by a single oncogene: boosting the effect on cyclin D1 activity. Cell Cycle 2008; 7:2299-305.
113. Kornblihtt AR, Schor IE, Allo M, Blencowe BJ. When chromatin meets splicing. Nat Struct Mol Biol 2009; 16:902-3.
114. Schor IE, Kornblihtt AR. Playing inside the genes: Intragenic histone acetylation after membrane depolarization of neural cells opens a path for alternative splicing regulation. Commun Integr Biol 2009; 2:341-3.
115. Allo M, Buggiano V, Fededa JP, Petrillo E, Schor I, de la Mata M, et al. Control of alternative splicing through siRNA-mediated transcriptional gene silencing. Nat Struct Mol Biol 2009; 16:717-24.
116. Schwartz S, Meshorer E, Ast G. Chromatin organization marks exon-intron structure. Nat Struct Mol Biol 2009; 16:990-5.
117. Batsche E, Yaniv M, Muchardt C. The human SWI/SNF subunit Brm is a regulator of alternative splicing. Nat Struct Mol Biol 2006; 13:22-9.
118. DiFeo A, Martignetti JA, Narla G. The role of KLF6 and its splice variants in cancer therapy. Drug Resist Updat 2009; 12:1-7.
119. Coulombe-Huntington J, Lam KC, Dias C, Majewski J. Fine-scale variation and genetic determinants of alternative splicing across individuals. PLoS Genet 2009; 5:1000766.
120. Hull J, Campino S, Rowlands K, Chan MS, Copley RR, Taylor MS, et al. Identification of common genetic variation that modulates alternative splicing. PLoS Genet 2007; 3:99.
121. Taylor JK, Zhang QQ, Wyatt JR, Dean NM. Induction of endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by antisense oligonucleotides. Nat Biotechnol 1999; 17:1097-100.
122. Bruno IG, Jin W, Cote GJ. Correction of aberrant FGFR1 alternative RNA splicing through targeting of intronic regulatory elements. Hum Mol Genet 2004; 13:2409-20. (Pubitemid 39377845)
123. Bartel F, Harris LC, Wurl P, Taubert H. MDM2 and its splice variant messenger RNAs: expression in tumors and downregulation using antisense oligonucleotides. Mol Cancer Res 2004; 2:29-35. (Pubitemid 38167105)
124. Wan J, Sazani P, Kole R. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int J Cancer 2009; 124:772-7.
125. Brack SS, Silacci M, Birchler M, Neri D. Tumortargeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006; 12:3200-8. (Pubitemid 43837370)
126. Colnot DR, Roos JC, de Bree R, Wilhelm AJ, Kummer JA, Hanft G, et al. Safety, biodistribution, pharmacokinetics and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 2003; 52:576-82. (Pubitemid 37056133)
127. Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO, et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 2004; 64:7822-35. (Pubitemid 39446915)
128. van Alphen RJ, Wiemer EA, Burger H, Eskens FA. The spliceosome as target for anticancer treatment. Br J Cancer 2009; 100:228-32.
129. Soret J, Gabut M, Tazi J. SR proteins as potential targets for therapy. Prog Mol Subcell Biol 2006; 44:65-87.
130. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, et al. Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004; 279:24246-54. (Pubitemid 38725286)
131. Kaida D, Motoyoshi H, Tashiro E, Nojima T, Hagiwara M, Ishigami K, et al. Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA. Nat Chem Biol 2007; 3:576-83. (Pubitemid 47294395)
132. Kotake Y, Sagane K, Owa T, Mimori-Kiyosue Y, Shimizu H, Uesugi M, et al. Splicing factor SF3b as a target of the antitumor natural product pladienolide. Nat Chem Biol 2007; 3:570-5. (Pubitemid 47294394)